Centro de Pesquisa e Ensino em Oncologia de Santa Catarina - CEPEN

The trials here

What the 6 trials at this site are about, from their registry records.

Conditions

• Multiple myeloma3 trials
• Liver and biliary tract cancer1 trial
• Lung cancer1 trial
• Melanoma1 trial

Phase

• Phase 36 trials

Status

• Active, not recruiting3 trials
• Completed3 trials

Lead sponsor

• Hoffmann-La Roche3 trials
• Janssen Research & Development, LLC3 trials

Running trials

• Active, not recruiting

  A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma

  NCT05083169· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases

  NCT04603807· Phase 3· Hoffmann-La Roche· Source

• Active, not recruiting

  A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab

  NCT04770896· Phase 3· Hoffmann-La Roche· Source

Closed trials

• Completed

  A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma

  NCT03301220· Phase 3· Janssen Research & Development, LLC· Source

• Completed

  A Study of Subcutaneous Versus (vs.) Intravenous Administration of Daratumumab in Participants With Relapsed or Refractory Multiple Myeloma

  NCT03277105· Phase 3· Janssen Research & Development, LLC· Source

• Completed

  A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma

  NCT02908672· Phase 3· Hoffmann-La Roche· Source